Skip to main content

Ratio of observed over predicted rates for diagnosis of cognitive impairment of any stage

CBE ID
3729
Endorsement Status
Not Endorsed
1.0 New or Maintenance
New
Previous Endorsement Cycle
Fall 2022
Is Under Review
No
Next Maintenance Cycle
Fall 2027
E&M Cycle Comments

Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Fall 2022 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Fall 2022 “Intent to Submit.” Battelle took over the E&M work for the Fall 2022 cycle after developers and/or stewards submitted their full measure information to NQF, which for CBE #3729, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2024-02/3729.zip

Battelle took over the E&M work beginning with the public comment period to close the E&M committees for the post-comment meeting, convening the CSAC to render a final endorsement decision, and executing the appeals period.

 

1.6 Measure Description
The measure captures the ratio of the number of patients, who are attributed to a clinician or practice, with a diagnosis of any stage of cognitive impairment over the expected number of cases based on a predictive model. Once the clinician’s or practice’s O/E ratio (i.e., ratio of the observed and expected rates) is calculated, a computation of its associated standard error (SE) can be used to draw inference whether the O/E ratio is significantly different from 1 or not.
Measure Specs
General Information
1.7 Measure Type
Process